Kilitch Drugs (India) Limited share price
NSE: KILITCH · ISIN INE729D01010
Key numbers
- Market cap
- ₹ 784 Cr
- Current price
- ₹ 224.27
- 52-week high / low
- ₹ 233 / 117
- Stock P/E
- 25.5
- Book value
- ₹ 80.0
- Dividend yield
- 0.00%
- ROCE
- 14.3%
- ROE
- 12.5%
- Debt to equity
- 0.32
- Sales growth (3 yrs)
- 19.2%
- Profit growth (3 yrs)
- 42.4%
- 1-year return
- 27.3%
About Kilitch Drugs (India) Limited
Kilitch Drugs (India) Limited engages in the development and operation of the pharmaceutical business in India and internationally. The company offers various parenteral, nasal, and topical products, such as liquid ampoules, vials, dry powder injectables, and metered nasal drops for gastroenterology, non-steroidal anti-inflammatory, anticonvulsant/antiepileptic, anti-malarial, aminoglycoside, antibacterial, anti-hypertensive, anti-infective, diagnostic, sympathomimetic, local anesthetic, neurotonic, uterine stimulant, external preparation, anticoagulant, narcotic, oncology, ophthalmic, antifungal, corticosteroid, anticoagulant, and other applications, as well as vaccines, veterinary products, iron supplements for anemia, Klavmox, and Onecef. It also provides oral formulations, including tablets, capsules, dry syrup, and oral powder for antibiotic, anti-diabetic, cardiovascular, and other areas; effervescent tablets and powders, such as Roipar, Duregra, and Roivit; and nutritional products, including Celtine. In addition, the company offers cosmetics, which include oil, lotion, liquid to cream, paste in skin, and personal and hair care products; herbal products for use in sore…
Quarterly results
Consolidated figures in ₹ crores
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 43 | 49 | 54 | 90 | 45 |
| Operating profit | 3 | 5 | 6 | 22 | 3 |
| Net profit | 3 | 8 | 4 | 15 | 3 |
| EPS (₹) | 0.94 | 2.48 | 1.25 | 4.24 | 0.83 |
Peers in Drug Manufacturers - Specialty & Generic
Data for information only, not investment advice. Prices end of day.